Evidence map›Paper›PMID 35688146›Full record

ArticleCell2022

Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq.

Joseph M Replogle, Reuben A Saunders, Angela N Pogson, Jeffrey A Hussmann, Alexander Lenail, Alina Guna, Lauren Mascibroda, Eric J Wagner, Karen Adelman, Gila Lithwick-Yanai and 7 more

Open access · hybridAbstract read
In one paragraph

Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 446 papers.

0numbers the graph read from it
0cells of the map it votes in
446citing papers in PubMed
49.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

446 citing papers in PubMed, 598 citations in OpenAlex.

  1. Review
  2. Latent causal diffusions for single-cell perturbation modeling.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

386 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Joseph M ReplogleMedical Scientist Training Program, University of California, San Francisco, San Francisco, CA 94158, USA; Tetrad Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Reuben A SaundersTetrad Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Angela N PogsonDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Jeffrey A HussmannDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Alexander LenailHoward Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Alina GunaWhitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Lauren MascibrodaDepartment of Biochemistry & Molecular Biology, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Eric J WagnerDepartment of Biochemistry & Molecular Biology, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA; Department of Biochemistry & Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.
Karen AdelmanDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Gila Lithwick-YanaiUltima Genomics, Newark, CA 94560, USA.
Nika IremadzeUltima Genomics, Newark, CA 94560, USA.
Florian OberstrassUltima Genomics, Newark, CA 94560, USA.
Doron LipsonUltima Genomics, Newark, CA 94560, USA.
Jessica L BonnarDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA.
Marco JostDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Microbiology, Harvard Medical School, Boston, MA 02115, USA.
Thomas M NormanProgram for Computational and Systems Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: normantm@mskcc.org.
Jonathan S WeissmanDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02142, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA. Electronic address: weissman@wi.mit.edu.
Howard Hughes Medical Institute · USHarvard University · USMemorial Sloan Kettering Cancer Center · USThe University of Texas Medical Branch at Galveston · USUniversity of Rochester · USWhitehead Institute for Biomedical Research · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human DiseaseRM1HG009490 · NHGRI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI Brittany S. Adamson, Martin Joseph Ankrah Aryee · 2017 to 2026
$22.7M
Cell Growth Signaling in Cancer DevelopmentR01CA129105 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI WEISSMAN, JONATHAN S. · 2008 to 2021
$5.9M
Probing the specificity and activity of the metazoan Integrator complexR01GM134539 · NIGMS · HARVARD MEDICAL SCHOOL · PI Karen L Adelman, ERIC J WAGNER · 2019 to 2026
$4.7M
Graduate Training in Computational and Systems BiologyT32GM087237 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B · 2009 to 2023
$4.6M
Predictive engineering of cellular transcriptional stateDP2GM140925 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI NORMAN, THOMAS MAXWELL · 2020 to 2020
$2.7M
Novel sequencing by synthesis platform to greatly reduce the cost of nucleic acid sequencingR44HG010558 · NHGRI · ULTIMA GENOMICS, INC. · PI PRATT, MARK ROBIN · 2019 to 2019
$2.2M
Novel sequencing by synthesis chemistry to further reduce the cost of nucleic acid sequencingR44HG011060 · NHGRI · ULTIMA GENOMICS, INC. · PI MAZUR, DANIEL JOSEPH · 2020 to 2021
$2.0M
Deciphering the logic of glycolipid signaling at the host-microbiome interfaceR00GM130964 · NIGMS · HARVARD MEDICAL SCHOOL · PI JOST, MARCO · 2021 to 2023
$747k
The role of TMA7 in mitochondrial dysfunctionF31NS115380 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI REPLOGLE, JOSEPH · 2019 to 2020
$75k
Howard Hughes Medical InstituteNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA129105NHGRI NIH HHS R44 HG010558NHGRI NIH HHS R44 HG011060NHGRI NIH HHS RM1 HG009490NIGMS NIH HHS DP2 GM140925NIGMS NIH HHS R00 GM130964NIGMS NIH HHS R01 GM134539NIGMS NIH HHS T32 GM087237NINDS NIH HHS F31 NS115380
6 · The paper itself

Abstract

A central goal of genetics is to define the relationships between genotypes and phenotypes. High-content phenotypic screens such as Perturb-seq (CRISPR-based screens with single-cell RNA-sequencing readouts) enable massively parallel functional genomic mapping but, to date, have been used at limited scales. Here, we perform genome-scale Perturb-seq targeting all expressed genes with CRISPR interference (CRISPRi) across >2.5 million human cells. We use transcriptional phenotypes to predict the function of poorly characterized genes, uncovering new regulators of ribosome biogenesis (including CCDC86, ZNF236, and SPATA5L1), transcription (C7orf26), and mitochondrial respiration (TMEM242). In addition to assigning gene function, single-cell transcriptional phenotypes allow for in-depth dissection of complex cellular phenomena-from RNA processing to differentiation. We leverage this ability to systematically identify genetic drivers and consequences of aneuploidy and to discover an unanticipated layer of stress-specific regulation of the mitochondrial genome. Our information-rich genotype-phenotype map reveals a multidimensional portrait of gene and cellular function.

Indexed as

GenomicsSingle-Cell AnalysisChromosome MappingCRISPR-Cas SystemsGenotypePhenotypecell biologychromosomal instabilityCRISPRgenetic screensgenotype-phenotype mapIntegrator complexmitochondrial genome stress responsePerturb-seqsingle-cell RNA sequencing

Identifiers

PMID35688146
PMCPMC9380471
OpenAlexW4281716291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.